#BEGIN_DRUGCARD DB00021

# AHFS_Codes:
Not Available

# ATC_Codes:
V04CK01

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
SecreFlo
Secremax, SecreFlo (Repligen Corp)

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C130H219N43O42

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>DB00021 sequence
HSDGTFTSELSRLRDSARLQRLLQGLV

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
874000

# Description:
This drug is the synthetic form of natural secretin.  It is prepared using solid phase peptide synthesis.  Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small  intestineâ€™s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered.

# Dosage_Forms:
Injection, powder, lyophilized, for solution	Intravenous

# Drug_Category:
Diagnostic Agents

# Drug_Interactions:
Clidinium	Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely.
Tiotropium	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Tolterodine	The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trihexyphenidyl	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trimethobenzamide	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.
Trospium	The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Biotech
Investigational

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.463

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Secretin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For diagnosis of pancreatic exocrine dysfunction and gastrinoma

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
21

# Mechanism_Of_Action:
Secretin binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach. Binding leads to the secrection of bicarbonate or the reduction of the secretion of gastrin. Properly functioning organs (duodenum, pancreas and stomach) should be responsive to this hormone

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
3056.4000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1OMN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164760844

# Pharmacology:
Used in the diagnosis of pancreatic dysfunction or gastrinoma (stomach cancer), secretin is a hormone produced in the S cells of the duodenum in response to low local pH. It stimulates the secretion of bicarbonate from bicarbonate producing organs(liver, pancreas, Brunner's glands) when the pH drops below a set value. This helps neutralize the gastric acid entering the duodenum from the stomach. It also inhibits acid secretion from the stomach by reducing gastrin release from the G cells of the stomach.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00021

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic3/secretin.htm

# Salts:
Not Available

# Secondary_Accession_No:
BIOD00039
BTD00039

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Secremax, SecreFlo

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2012-06-14 11:21:08 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Secretin

# pKa_Isoelectric_Point:
9.45

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SCTR

# Drug_Target_1_GenBank_ID_Gene:
U20178

# Drug_Target_1_GenBank_ID_Protein:
662796

# Drug_Target_1_GeneCard_ID:
SCTR

# Drug_Target_1_Gene_Name:
SCTR

# Drug_Target_1_Gene_Sequence:
>1323 bp
ATGCGTCCCCACCTGTCGCCGCCGCTGCAGCAGCTACTACTGCCGGTGCTGCTCGCCTGC
GCCGCGCACTCGACTGGAGCCCTTCCCCGACTATGTGACGTGCTACAAGTGCTGTGGGAA
GAGCAAGACCAGTGCCTGCAGGAACTCTCCAGAGAGCAGACAGGAGACCTGGGCACGGAG
CAGCCAGTGCCAGGTTGTGAGGGGATGTGGGACAACATAAGCTGCTGGCCCTCTTCTGTG
CCGGGCCGGATGGTGGAGGTGGAATGCCCGAGATTCCTCCGGATGCTCACCAGCAGAAAT
GGTTCCTTGTTCCGAAACTGCACACAGGATGGCTGGTCAGAAACCTTCCCCAGGCCTAAT
CTGGCCTGTGCGGTTAATGTGAACGACTCTTCCAACGAGAAGCGGCACTCCTACCTGCTG
AAGCTGAAAGTCATGTACACCGTGGGCTACAGCTCCTCCCTGGTCATGCTCCTGGTCGCC
CTTGGCATCCTCTGTGCTTTCCGGAGGCTCCACTGCACTCGCAACTACATCCACATGCAC
CTGTTCGTGTCCTTCATCCTTCGTGCCCTGTCCAACTTCATCAAGGACGCCGTGCTCTTC
TCCTCAGATGATGTCACCTACTGCGATGCCCACAGGGCGGGCTGCAAGCTGGTCATGGTG
CTGTTCCAGTACTGCATCATGGCCAACTACTCCTGGCTGCTGGTGGAAGGCCTCTACCTT
CACACACTCCTCGCCATCTCCTTCTTCTCTGAAAGAAAGTACCTCCAGGGATTTGTGGCA
TTCGGATGGGGTTCTCCAGCCATTTTTGTTGCTTTGTGGGCTATTGCCAGACACTTTCTG
GAAGATGTTGGGTGCTGGGACATCAATGCCAACGCATCCATCTGGTGGATCATTCGTGGT
CCTGTGATCCTCTCCATCCTGATTAATTTCATCCTTTTCATAAACATTCTAAGAATCCTG
ATGAGAAAACTTAGAACCCAAGAAACAAGAGGAAATGAAGTCAGCCATTATAAGCGCCTG
GCCAGGTCCACTCTCCTGCTGATCCCCCTCTTTGGCATCCACTACATCGTCTTCGCCTTC
TCCCCAGAGGACGCTATGGAGATCCAGCTGTTTTTTGAACTAGCCCTTGCGTCATTCCAG
GGACTGGTGGTGGCCGTCCTCTACTGCTTCCTCAACGGGGAGGTGCAGCTGGAGGTTCAG
AAGAAGTGGCAGCAATGGCACCTCCGTGAGTTCCCACTGCACCCCGTGGCCTCCTTCAGC
AACAGCACCAAGGCCAGCCACTTGGAGCAGAGCCAGGGCACCTGCAGGACCAGCATCATC
TGA

# Drug_Target_1_General_Function:
Involved in G-protein coupled receptor activity

# Drug_Target_1_General_References:
7612008	Chow BK: Molecular cloning and functional characterization of a human secretin receptor. Biochem Biophys Res Commun. 1995 Jul 6;212(1):204-11.
7700244	Patel DR, Kong Y, Sreedharan SP: Molecular cloning and expression of a human secretin receptor. Mol Pharmacol. 1995 Mar;47(3):467-73.
7864894	Jiang S, Ulrich C: Molecular cloning and functional expression of a human pancreatic secretin receptor. Biochem Biophys Res Commun. 1995 Feb 27;207(3):883-90.

# Drug_Target_1_HGNC_ID:
HGNC:10608

# Drug_Target_1_HPRD_ID:
01628

# Drug_Target_1_ID:
352

# Drug_Target_1_Locus:
2q14.1

# Drug_Target_1_Molecular_Weight:
50207

# Drug_Target_1_Name:
Secretin receptor

# Drug_Target_1_Number_of_Residues:
440

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00002	7tm_2
PF02793	HRM

# Drug_Target_1_Protein_Sequence:
>Secretin receptor precursor
MRPHLSPPLQQLLLPVLLACAAHSTGALPRLCDVLQVLWEEQDQCLQELSREQTGDLGTE
QPVPGCEGMWDNISCWPSSVPGRMVEVECPRFLRMLTSRNGSLFRNCTQDGWSETFPRPN
LACGVNVNDSSNEKRHSYLLKLKVMYTVGYSSSLVMLLVALGILCAFRRLHCTRNYIHMH
LFVSFILRALSNFIKDAVLFSSDDVTYCDAHRAGCKLVMVLFQYCIMANYSWLLVEGLYL
HTLLAISFFSERKYLQGFVAFGWGSPAIFVALWAIARHFLEDVGCWDINANASIWWIIRG
PVILSILINFILFINILRILMRKLRTQETRGNEVSHYKRLARSTLLLIPLFGIHYIVFAF
SPEDAMEIQLFFELALGSFQGLVVAVLYCFLNGEVQLEVQKKWQQWHLREFPLHPVASFS
NSTKASHLEQSQGTCRTSII

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-22

# Drug_Target_1_Specific_Function:
This is a receptor for secretin. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase

# Drug_Target_1_SwissProt_ID:
P47872

# Drug_Target_1_SwissProt_Name:
SCTR_HUMAN

# Drug_Target_1_Synonyms:
SCT-R
Secretin receptor precursor

# Drug_Target_1_Theoretical_pI:
7.77

# Drug_Target_1_Transmembrane_Regions:
144-167
175-194
217-240
255-276
295-317
344-362
370-392

#END_DRUGCARD DB00021
